SEC Form 4 · accession 0001533568-26-000012
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leslie V Norwalk
Director
Period of report
Jul 28, 2026
Accepted (ET)
Jul 30, 2026 · 5:29 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 28, 2026 | S | 1,250 | $182.006 | D | 1,588 | D | |
| Common Stock | Jul 29, 2026 | M | 842 | $139.43 | A | 2,430 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF3 | $139.43 | Jul 29, 2026 | M | 842 | D | — | May 22, 2034 | Common Stock | 842 | 2,140 | D |
Explanation of responses
- F1The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $182.00 to $182.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Option vested in 12 monthly installments beginning June 22, 2024.